北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
作者: Zhu, Xuejun1; Zheng, Min2; Song, Michael3; Shen, Yaung-Kaung4; Chan, Daphne3; Szapary, Philippe O.3; Wang, Baoxi5; LOTUS Investigators
刊名: JOURNAL OF DRUGS IN DERMATOLOGY
发表日期: 2013-02-01
卷: 12, 期:2, 页:166-174
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Dermatology
研究领域[WOS]: Dermatology
关键词[WOS]: PLACEBO-CONTROLLED TRIAL ; TO-SEVERE PSORIASIS ; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY ; LATENT TUBERCULOSIS INFECTION ; DOUBLE-BLIND TRIAL ; HAN POPULATION ; FOLLOW-UP ; THERAPY ; POLYMORPHISMS ; MULTICENTER
英文摘要:

Background: Available biologic agents for the treatment of psoriasis in China are limited.

Objectives: The LOTUS study is a phase 3, double-blind, placebo-controlled study that evaluated the efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis.

Patients and Methods: Patients (n=322) were randomized to receive ustekinumab 45 mg or placebo at weeks 0 and 4, with placebo crossover to ustekinumab at week 12; all patients were followed up to week 36. The primary end point was the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. Other end points at week 12 included the proportion of patients with a Physician′s Global Assessment (PGA) score of 0 or 1 and the change in Dermatology Life Quality Index (DLQI) score from baseline.

Results: At week 12, 82.5% of ustekinumab-treated patients achieved PASI 75 responses compared with 11.1% of placebo-treated patients (P<.001). Clinical responses were maintained through week 28, with maximum responses observed at week 24. Significant improvements in PGA and DLQI were observed at week 12 and were generally maintained through week 28. At week 12, adverse events rates were similar between groups (45 mg: 42.5% vs placebo: 38.5%), and serious adverse events were reported in 0.6% of patients in each group. Through week 36, no cases of active tuberculosis, serious infections, malignancies, or major adverse cardiovascular events were reported.

Conclusions: Consistent with results previously reported in global phase 3 studies, ustekinumab was highly effective and generally well tolerated in Chinese patients with moderate to severe psoriasis through 36 weeks. J Drugs Dermatol. 2013;12(2):166-174.

语种: 英语
项目资助者: Janssen Research &amp ; Development, LLC. ; Janssen Research Development
WOS记录号: WOS:000314625700006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53818
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Dept Dermatol & Venerol, Beijing 100871, Peoples R China
2.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Dermatol & Venerol, Hangzhou 310003, Zhejiang, Peoples R China
3.Janssen Res & Dev LLC, Dept Immunol, Spring House, PA USA
4.Janssen Res & Dev LLC, Dept Biostat, Spring House, PA USA
5.Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China

Recommended Citation:
Zhu, Xuejun,Zheng, Min,Song, Michael,et al. Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)[J]. JOURNAL OF DRUGS IN DERMATOLOGY,2013,12(2):166-174.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhu, Xuejun]'s Articles
[Zheng, Min]'s Articles
[Song, Michael]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhu, Xuejun]‘s Articles
[Zheng, Min]‘s Articles
[Song, Michael]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace